BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nadella V, Sharma L, Kumar P, Gupta P, Gupta UD, Tripathi S, Pothani S, Qadri SSYH, Prakash H. Sphingosine-1-Phosphate (S-1P) Promotes Differentiation of Naive Macrophages and Enhances Protective Immunity Against Mycobacterium tuberculosis. Front Immunol 2019;10:3085. [PMID: 32038629 DOI: 10.3389/fimmu.2019.03085] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Prakash H, Upadhyay D, Bandapalli OR, Jain A, Kleuser B. Host sphingolipids: Perspective immune adjuvant for controlling SARS-CoV-2 infection for managing COVID-19 disease. Prostaglandins Other Lipid Mediat 2021;152:106504. [PMID: 33147503 DOI: 10.1016/j.prostaglandins.2020.106504] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
2 Phelan JJ, O'Leary S, Keane J. Tuberculosis lymph node granulomas: using transcriptomics to discover immunopathology paradigms and guide host-directed therapy. J Clin Invest 2021;131:151810. [PMID: 34338227 DOI: 10.1172/JCI151810] [Reference Citation Analysis]
3 Chatterjee R, Chowdhury AR, Mukherjee D, Chakravortty D. Lipid larceny: channelizing host lipids for establishing successful pathogenesis by bacteria. Virulence 2021;12:195-216. [PMID: 33356849 DOI: 10.1080/21505594.2020.1869441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Toor D, Jain A, Kalhan S, Manocha H, Sharma VK, Jain P, Tripathi V, Prakash H. Tempering Macrophage Plasticity for Controlling SARS-CoV-2 Infection for Managing COVID-19 Disease. Front Pharmacol 2020;11:570698. [PMID: 33178021 DOI: 10.3389/fphar.2020.570698] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Chen X, Ye J, Lei H, Wang C. Novel Potential Diagnostic Serum Biomarkers of Metabolomics in Osteoarticular Tuberculosis Patients: A Preliminary Study. Front Cell Infect Microbiol 2022;12:827528. [DOI: 10.3389/fcimb.2022.827528] [Reference Citation Analysis]
6 Naz F, Arish M. GPCRs as an emerging host-directed therapeutic target against mycobacterial infection: From notion to reality. Br J Pharmacol 2020. [PMID: 33150959 DOI: 10.1111/bph.15315] [Reference Citation Analysis]